Entropy Neurodynamics Limited (ASX:ENP)

Entropy Neurodynamics Limited announced that it has been granted a South African patent covering methods of treating fibromyalgia using psilocybin and psilocin-based treatments. This patent significantly strengthens Entropy's global intellectual property estate by providing broad protection encompassing treatment methods, dosing regimens, patient selection, clinical protocols, biomarkers, outcome measures, and manufacturing. The patent is designed to create significant commercial exclusivity for psychedelic-based fibromyalgia therapies in South Africa, with claims that are difficult for competitors to design around. The patent term extends to September 2043, supporting Entropy's long-term commercialization and partnering strategies. This grant expands Entropy's growing global IP portfolio that supports the development of TRP-8803, which is an IV-infused psilocin designed to meet large unmet medical needs. The strategic focus remains on building a robust global patent estate to enhance development programs and support future partnering opportunities.